Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Marco Fiorillo; Rebecca Lamb; Herbert B. B. Tanowitz; Anna Rita Rita Cappello; Ubaldo E. E. Martinez-Outschoorn; Federica Sotgia; Michael P. P. Lisanti

doi:doi:10.18632/aging.100983

← Back

Research Paper Volume 8, Issue 8 pp 1593—1606

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Figure 4. Bedaquiline reduces mitochondrial membrane potential, with a significant rise in ROS levels. FACS analysis was carried out on MCF7 cells treated with 10μM bedaquiline for 48 hours. (A, B) Bedaquiline reduces mitochondrial membrane potential (MitoTracker Orange), with a likely compensatory increase in mitochondrial mass (MitoTracker Deep-Red). (C) The ratio of mitochondrial membrane potential to mass indicates that bedaquiline reduces the membrane potential per mitochondria. (D) Cells were stained with the CM-H₂DCFDA probe and analyzed by FACS to determine ROS levels. Note that ROS levels are increased by bedaquiline treatment. * p<0.01, **** p<0.00001.